Mostrar el registro sencillo del ítem

dc.contributorUniversitat Ramon Llull. IQS
dc.contributor.authorMagaña Rodriguez, J. Rodrigo
dc.contributor.authorGuerra Rebollo, Marta
dc.contributor.authorBorrós i Gómez, Salvador
dc.contributor.authorFornaguera Puigvert, Cristina
dc.date.accessioned2024-12-20T08:42:25Z
dc.date.available2024-12-20T08:42:25Z
dc.date.issued2024-05-03
dc.identifier.issn2190-3948ca
dc.identifier.urihttp://hdl.handle.net/20.500.14342/4655
dc.description.abstractImmunotherapy has emerged as a promising approach to cancer treatment, offering improved survival rates and enhanced patients’ quality of life. However, realizing the full potential of immunotherapy in clinical practice remains a challenge, as there is still plenty of room for modulating the complexity of the human immune system in favor of an antitumor immunogenicity. Nanotechnology, with its unique properties, holds promise in augmenting the efficacy of cancer immunotherapies in biotherapeutic protection and site- and time-controlled delivery of the immune modulator biologicals. Polymeric nanoparticles are promising biomaterials among different nanocarriers thanks to their robustness, versatility, and cost-efficient design and production. This perspective paper overviews critical concepts in nanometric advanced delivery systems applied to cancer immunotherapy. We focus on a detailed exploration of the current state of the art and trends in using poly(beta-aminoester) (pBAE) polymers for nucleic acid-based antitumor immunotherapies. Through different examples of the use of pBAE polymers reported in the literature, we revise the main advantages these polymers offer and some challenges to overcome. Finally, the paper provides insights and predictions on the path toward the clinical implementation of cancer nano-immunotherapies, highlighting the potential of pBAE polymers for advancements in this field.ca
dc.format.extent17 p.ca
dc.language.isoengca
dc.publisherSpringer Natureca
dc.relation.ispartofDrug Delivery and Translational Research. 2024;14:3477–3493ca
dc.rights© L'autor/aca
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.otherPoly(beta aminoesters)ca
dc.subject.otherCancer immunotherapiesca
dc.subject.otherPolymeric nanoparticlesca
dc.subject.otherNucleic acids therapeuticsca
dc.subject.otherControlled deliveryca
dc.titleNucleic acid-loaded poly(beta-aminoester) nanoparticles for cancer nano-immuno therapeuticsca
dc.title.alternativethe good, the bad, and the futureca
dc.typeinfo:eu-repo/semantics/articleca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc575ca
dc.identifier.doihttps://doi.org/10.1007/s13346-024-01585-yca
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/PN I+D/AC22/00042ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/FCAECC/PN I+D/TRNSC213882FORNca
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/PN I+D/PID2021-125910OB-I00ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/Marie Skłodowska-Curie/801342ca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca


Ficheros en el ítem

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

© L'autor/a
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by/4.0/
Compartir en TwitterCompartir en LinkedinCompartir en FacebookCompartir en TelegramCompartir en WhatsappImprimir